GSK plc’s Jemperli Court Fight With AnaptysBio Takes New Turn Before July Trial
Tesaro, GSK plc’s U.S. oncology arm, saw a setback in its Delaware case over Jemperli—part of its claim against AnaptysBio was tossed. The court dismissed Tesaro’s anticipatory breach argument. GSK, though, noted that the main dispute over the contract is still in play, and Tesaro’s request for declaratory judgment remains. Timing’s key here. GSK is set to deliver first-quarter 2026 numbers on Wednesday, April 29, with investors zeroed in on whether oncology will keep doing the heavy lifting as older segments of the portfolio come under strain.